Impact of pharmacological spasm provocation test in patients with a history of syncope

Shozo Sueda1, Hiroaki Kohno2

  • 1Department of Cardiology, Ehime Prefectural Niihama Hospital, Hongou 3 Choume 1-1, Niihama, Ehime, 792-0042, Japan. EZF03146@nifty.com.

Heart and Vessels
|September 15, 2017
PubMed

Insights

Coronary artery spasm, a cause of cardiac issues, was found in 75% of syncope patients. This suggests investigating coronary artery spasm in patients experiencing syncope, even without chest pain.

Area of Science:

  • Cardiology
  • Vascular Medicine

Background:

  • Coronary artery spasm contributes to various cardiac disorders.
  • Syncope is a significant clinical symptom requiring etiological investigation.

Purpose of the Study:

  • To investigate the prevalence and characteristics of coronary artery spasm in patients presenting with syncope.
  • To determine if coronary artery spasm is a potential cause of syncope, particularly in the absence of typical chest symptoms.

Main Methods:

  • Retrospective analysis of 5781 patients undergoing coronary angiography over 26 years.
  • Pharmacological spasm provocation testing in 64 patients with a history of syncope.
  • Evaluation of coronary artery spasm based on transient vessel narrowing and electrocardiographic changes.

Main Results:

  • Out of 95 patients with syncope history, 64 underwent spasm testing.
  • Positive spasm was observed in 48 patients, with definite coronary spastic angina (CSA) in 35 (54.7%).
  • CSA was diagnosed in 75% of patients with syncope within one year, including 13 patients without chest symptoms.

Conclusions:

  • Coronary artery spasm is a significant finding in patients with syncope.
  • Coronary artery spasm should be considered as a potential cause of syncope, even in the absence of chest pain or pressure.
  • Further investigation into coronary artery spasm is warranted for patients with a history of syncope.

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.8K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
1.1K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
930
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.2K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
646
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.4K